IP Library Patent Application 10515714
Patent Application
App. No. 10/515,714

Self-administered contraceptive injection of oily solution

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/515,714
Abstract

The subject invention provides a pharmaceutical formulation in the form of an oily solution for injection to a subject comprising a contraceptively and/or therapeutically effective amount of a long-acting progestogen and a contraceptively and/or therapeutically effective amount of a long-acting androgen dissolved in a pharmaceutically acceptable oily medium wherein the injection is administered by the subject itself with a needle-less device, a mini-needle device or a pre-filled subcutaneous syringe.

Claims (10)

1 - 72 . (canceled)

73 . An oily solution for injection to a subject comprising a 50-400 mg/ml of a long-acting progestogen and 25-200 mg/ml of a long-acting androgen dissolved in a pharmaceutically acceptable oily medium.

74 . A solution according to claim 1 wherein the long acting progestogen is an ester with a fatty chain length of C7 to C15.

75 . A solution according to claim 2 wherein the long acting progestogen is an ester or a progestogen selected from the group consisting of ethisterone, norethisterone, dimethisterone, norethynodrel, norgestrienone, lynestrenol, ethynodiol, norgestrel, levo-norgestrel, desogestrel, gestodene, allylestrenol, etonogestrel and dienogest.

76 . A solution according to claim 3 wherein the ester of progestogen is etonogestrel undecanoate.

77 . A solution according to claim 1 wherein the long-acting androgen is an ester with a fatty chain length of C6 to C12.

78 . A solution according to claim 5 wherein the long-acting androgen is an ester of testosterone or an ester of 7-alpha-methyl-19-nortestosterone.

79 . A solution according to claim 6 wherein the ester of the androgen is 7-alpha-methyl-19-nortestostetone undecanoate.

80 . A solution according to claim 1 wherein the oily medium is arachis oil or ethyl undecanoate.

81 . A needle-less device, a mini-needle device or a pre-filled subcutaneous syringe, each for injection administration by the subject himself, comprising less than 1 millilitre of the solution according to claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2007
From: AKZO NOBEL N.V.
To: N.V. ORGANON
Reel/Frame 018816/0737 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2005
From: DE NIJS, HENDRIK; VAN DER VOORT, HENDRIKUS ADRIANUS ANTONIUS; LEYSEN, DIRK
To: AKZO NOBEL N.V.
Reel/Frame 016273/0497 →